ClinicalTrials.gg
Active, not recruitingNCT03732677NIAGARAUpdated Oct 15, 2026Results posted

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

A Phase 3 interventional study of Durvalumab and Cisplatin in Muscle Invasive Bladder Cancer, sponsored by AstraZeneca. Active, not recruiting at 188 sites in 22 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,063
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing durvalumab in Urinary Bladder Neoplasms — 4 open to participants now, 12 under way, 3 of them phase 3. durvalumab · Urinary Bladder Neoplasms.

Enrollment
2nd of 19
1,063 · median 39
Started
2018
with 4 others
Phase 3
3 of 19
none open now
Primary completion
2024-04
later than 0 of 11 live
Registered
7th of 19
by date
Lead sponsor
5 of 19
AstraZeneca

Among the 19 studies testing durvalumab in Urinary Bladder Neoplasms, this one is the 2nd largest by enrollment, is one of 5 that started in 2018, is one of 3 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 7th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

4 of the 19 studies testing durvalumab in Urinary Bladder Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing durvalumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

03

Conditions studied

  • Muscle Invasive Bladder Cancer

Keywords

  • Bladder Cancer
  • Immunotherapy
  • PD-L1
  • Durvalumab (MEDI4736)
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient resectable muscle-invasive bladder cancer with clinical stage T2-T4aN0/1M0 with transitional and mixed transitional cell histology
  • Patients must be planning to undergo a radical cystectomy
  • Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC
  • performance status of 0 or 1
  • Must have a of at least 12 weeks at randomization

Exclusion criteria

Exclusion:

  • Evidence of lymph node (N2-N3) or (M1) disease at time of screening.
  • Prior pelvic radiotherapy treatment within 2 years of randomization to study
  • Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other , anti-PD-1, anti PD-L1, or anti-PD-L2 antibodies.
  • Current or prior use of medication within 14 days before the first dose of product (IP). The following are exceptions to this criterion: Intranasal, inhaled, topical , or local steroid injections (eg, intra articular injection); Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; Steroids as premedication for reactions (eg, CT scan premedication)
  • Receipt of within 30 days prior to the first dose of IP.
  • Uncontrolled intercurrent illness
  • Active infection including Tuberculosis, , , and Human Immunodeficiency
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,063 participants (actual)

Study arms

  • Experimental
    Arm 1

    Chemotherapy + Durvalumab

    Drug: Durvalumab · Drug: Cisplatin · Drug: Gemcitabine

  • Active comparator
    Arm 2

    Chemotherapy alone

    Drug: Cisplatin · Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Pathologic Complete Response (pCR) Rates at Time of Cystectomy

    pCR rate is defined as the proportion of patients whose pathological staging was T0N0M0 as assessed per central pathology review using specimens obtained via radical cystectomy following the neoadjuvant treatment. The denominator for pCR will be the number of patients in the FAS.

    Time frame: Up to 6 months

  2. Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event

    EFS is defined as the time from randomization to the first recurrence of disease post radical cystectomy, time of first documented progression in patients who were medically precluded for radical cystectomy, or time of expected surgery in patients who refuse to undergo a radical cystectomy or failure to undergo a radical cystectomy in participants with residual disease, or the time of death due to any cause, whichever occurs first

    Time frame: Up to 48 months

Secondary outcomes

  1. Event-free Survival at 24 Months (EFS24) Per Central Review Defined as Time From Randomization to Event

    EFS24 is defined as the Kaplan-Meier estimate of EFS at 24 months after randomization, as assessed per blinded independent central review or by central pathology review if a biopsy is required for a suspected new lesion, and per local investigator or local biopsy review if a biopsy is required for a suspected new lesion

    Time frame: Up to 24 months

  2. Proportion of Patients Who Undergo Cystectomy

    The proportion of patients who undergo cystectomy is defined as the proportion patients who undergo radical cystectomy after the neoadjuvant treatment. The denominator will be patients in the FAS.

    Time frame: Up to 6 months

  3. Overall Survival

    OS is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e., date of death or censoring - date of randomization + 1)

    Time frame: Up to 65 months

  4. Metastasis-free Survival Per Investigator Assessment or Local Biopsy Review.

    MFS is defined as the time from date of randomization until the first recognition of distant metastases or death, whichever occurs first

    Time frame: Up to 48 months

  5. Disease-specific Survival Per Investigator Assessment or Local Biopsy Review.

    DSS is defined as the time from the date of randomization until death due to bladder cancer

    Time frame: Up to 48 months

  6. Immunogenicity of Durvalumab When Used in Combination With Gemcitabine/Cisplatin as Measured by Presence of Antidrug Antibodies (ADA)

    Whole blood samples for assessing ADA for durvalumab in serum were collected from patients undergoing durvalumab treatment, following the specified assessment schedule. ADA prevalence is the proportion of patients with a positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA includes both treatment-induced and treatment-boosted ADA. Its incidence is the proportion of patients with treatment-emergent ADA positivity. Treatment-boosted ADA refers to a baseline-positive ADA titer that increased ≥4-fold during the study. Persistently positive patients have at least two post-baseline ADA-positive readings, with at least 16 weeks between the first and last, or an ADA-positive result at the final assessment. This includes baseline-positive patients meeting these criteria. Transiently positive is defined by at least one post-baseline ADA-positive reading without being persistently positive, including baseline-positive patients meeting these terms.

    Time frame: Up to 12 months

07

Results

Posted Jul 3, 2025

Participant flow

Patients randomized to treatments Arm 1 or Arm 2, will be treated according to their renal function. Recruitment for borderline renal function patients will be limited to up to 20% of the targeted global population. Recruitment for patients with T2N0 disease will be limited to approximately 40% of the targeted global population; once the 40% cap has been reached, only T2-4N1M0 and T3-4N0M0 patients will be allowed to be enrolled onto the study. Completion status is reported by treatment phase

Participant flow — Overall Study
MilestoneDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Started533530
Started neoadjuvant treatment530526
Completed neoadjuvant treatment417389
Completed radical cystectomy469441
Started adjuvant treatment3830
Completed adjuvant treatment2880
Completed00
Not completed533530
Withdrew: Terminated the study154197
Withdrew: Continuing study off treatment379333

Outcome measures

PrimaryPathologic Complete Response (pCR) Rates at Time of Cystectomy

pCR rate is defined as the proportion of patients whose pathological staging was T0N0M0 as assessed per central pathology review using specimens obtained via radical cystectomy following the neoadjuvant treatment. The denominator for pCR will be the number of patients in the FAS.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Pathologic Complete Response (pCR) Rates at Time of Cystectomy
ParticipantsDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Pathologic Complete Response (pCR) Rates at Time of Cystectomy199146
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin · Regression, Logistic · p = 0.0005 · Odds ratio (or): 1.60 · 95% CI 1.227 to 2.084Strata adjusted odds ratio by the logistic regression method adjusting for stratification factors: renal function , tumor stage and PDL1 status .
PrimaryEvent-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event

EFS is defined as the time from randomization to the first recurrence of disease post radical cystectomy, time of first documented progression in patients who were medically precluded for radical cystectomy, or time of expected surgery in patients who refuse to undergo a radical cystectomy or failure to undergo a radical cystectomy in participants with residual disease, or the time of death due to any cause, whichever occurs first

Time frame:
Up to 48 months
Reported as:
Median · months
Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event
monthsDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to EventNA (13.4 to NA)46.1 (8.6 to NA)
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin · Log Rank · p = <0.0001 (Stratified by renal function(adequate vs borderline),tumor stage(T2N0 vs \>T2N0), PDL1 status(high vs low/negative)) · Hazard ratio (hr): 0.68 · 95.877% CI 0.554 to 0824The HR and CI were estimated from a stratified Cox proportional hazard model adjusting for renal function (adequate vs borderline), tumor stage (T2N0 vs \>T2N0) and PDL1 status (high vs low/negative)
SecondaryEvent-free Survival at 24 Months (EFS24) Per Central Review Defined as Time From Randomization to Event

EFS24 is defined as the Kaplan-Meier estimate of EFS at 24 months after randomization, as assessed per blinded independent central review or by central pathology review if a biopsy is required for a suspected new lesion, and per local investigator or local biopsy review if a biopsy is required for a suspected new lesion

Time frame:
Up to 24 months
Reported as:
Number · Percentage of participants
Event-free Survival at 24 Months (EFS24) Per Central Review Defined as Time From Randomization to Event
Percentage of participantsDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Event-free Survival at 24 Months (EFS24) Per Central Review Defined as Time From Randomization to Event67.8 (63.6 to 71.7)59.8 (55.4 to 64)
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin · Chi-squared · p = 0.0021 · Hazard ratio (hr): 0.75 · 95% CI 0.62 to 0.90The HR and CI were estimated from a stratified Cox proportional hazard model adjusting for renal function (adequate vs borderline), tumor stage (T2N0 vs \>T2N0) and PDL1 status (high vs low/negative)
SecondaryProportion of Patients Who Undergo Cystectomy

The proportion of patients who undergo cystectomy is defined as the proportion patients who undergo radical cystectomy after the neoadjuvant treatment. The denominator will be patients in the FAS.

Time frame:
Up to 6 months
Reported as:
Count of participants · Participants
Proportion of Patients Who Undergo Cystectomy
ParticipantsDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Proportion of Patients Who Undergo Cystectomy469441
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin · Regression, Logistic · p = 0.0265 · Odds ratio (or): 1.48 · 95% CI 1.047 to 2.095Strata adjusted odds ratio by the logistic regression method. Stratified by adjusting for renal function (adequate vs borderline), tumor stage (T2N0 vs \>T2N0) and PDL1 status (high vs low/negative).
SecondaryOverall Survival

OS is defined as the time from the date of randomization until death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another anti-cancer therapy (i.e., date of death or censoring - date of randomization + 1)

Time frame:
Up to 65 months
Reported as:
Median · Months
Overall Survival
MonthsDurvalumab+Gemcitabine+CisplatinGemcitabine+Cisplatin
Overall SurvivalNA (41.9 to NA)NA (24.1 to NA)
Statistical analysis
  • Durvalumab+Gemcitabine+Cisplatin vs Gemcitabine+Cisplatin · Log Rank · p = 0.0106 · Hazard ratio (hr): 0.75 · 98.457% CI 0.563 to 0.985Stratified by renal function (adequate vs borderline),tumor stage(T2N0vs \>T2N0), PDL1 status(high vs low/negative)
SecondaryMetastasis-free Survival Per Investigator Assessment or Local Biopsy Review.

MFS is defined as the time from date of randomization until the first recognition of distant metastases or death, whichever occurs first

Time frame:
Up to 48 months
Reported as:
Median · Months
Metastasis-free Survival Per Investigator Assessment or Local Biopsy Review.
MonthsDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Metastasis-free Survival Per Investigator Assessment or Local Biopsy Review.NA (24.2 to NA)NA (15 to NA)
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.67 · 95% CI 0.541 to 0.826The HR and CI were estimated from a stratified Cox proportional hazard model adjusting for renal function (adequate vs borderline), tumor stage (T2N0 vs \>T2N0) and PDL1 status (high vs low/negative)
SecondaryDisease-specific Survival Per Investigator Assessment or Local Biopsy Review.

DSS is defined as the time from the date of randomization until death due to bladder cancer

Time frame:
Up to 48 months
Reported as:
Median · months
Disease-specific Survival Per Investigator Assessment or Local Biopsy Review.
monthsDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Disease-specific Survival Per Investigator Assessment or Local Biopsy Review.NA (NA to NA)NA (50.9 to NA)
Statistical analysis
  • Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin · Log Rank · p = 0.0081 · Hazard ratio (hr): 0.69 · 95% CI 0.516 to 0.907The HR and CI were estimated from a stratified Cox proportional hazard model adjusting for renal function (adequate vs borderline), tumor stage (T2N0 vs \>T2N0) and PDL1 status (high vs low/negative)
SecondaryImmunogenicity of Durvalumab When Used in Combination With Gemcitabine/Cisplatin as Measured by Presence of Antidrug Antibodies (ADA)

Whole blood samples for assessing ADA for durvalumab in serum were collected from patients undergoing durvalumab treatment, following the specified assessment schedule. ADA prevalence is the proportion of patients with a positive ADA result at any time, baseline or post-baseline. Treatment-emergent ADA includes both treatment-induced and treatment-boosted ADA. Its incidence is the proportion of patients with treatment-emergent ADA positivity. Treatment-boosted ADA refers to a baseline-positive ADA titer that increased ≥4-fold during the study. Persistently positive patients have at least two post-baseline ADA-positive readings, with at least 16 weeks between the first and last, or an ADA-positive result at the final assessment. This includes baseline-positive patients meeting these criteria. Transiently positive is defined by at least one post-baseline ADA-positive reading without being persistently positive, including baseline-positive patients meeting these terms.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Immunogenicity of Durvalumab When Used in Combination With Gemcitabine/Cisplatin as Measured by Presence of Antidrug Antibodies (ADA)
ParticipantsDurvalumab + Gemcitabine + Cisplatin
ADA positive at any visit (ADA prevalence)37
Treatment-emergent ADA positive (ADA Incidence)8
Treatment-boosted ADA1
Treatment-induced ADA (Positive Post-baseline only)7
ADA Positive at Baseline only29
ADA Positive Post-baseline and Positive at Baseline1
Persistently Positive4
Transiently Positive4
nAb Positive at any visit6

Adverse events

Collected over Includes AEs between date of first dose and the earliest of: maximum date of (last dose or surgery) + 90days, date of first dose of subsequent anti-cancer therapy. Total follow up about 2 years. The frequency assessment was: Neoadjuvant, every 3 weeks, Post Surgery, every week, Adjuvant and Follow Up: every 4 weeks. All-cause mortality (death due to any cause): from randomization up to EFS IA2 DCO (April 29, 2024). Maximum timeframe of approximately 5.4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab + Gemcitabine + Cisplatin27/533 (5.1%)326/530 (61.5%)522/530 (98.5%)
Gemcitabine + Cisplatin29/526 (5.5%)287/526 (54.6%)511/526 (97.1%)
Most frequent serious events
Showing 10 of 305
Most frequent serious events
EventDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
Urinary tract infectionInfections and infestations59/53069/526
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)35/53027/526
Acute kidney injuryRenal and urinary disorders25/53024/526
PyelonephritisInfections and infestations19/53023/526
Prostate cancer stage iiNeoplasms benign, malignant and unspecified (incl cysts and polyps)21/53010/526
UrosepsisInfections and infestations20/53010/526
SepsisInfections and infestations19/53014/526
Pulmonary embolismRespiratory, thoracic and mediastinal disorders18/5305/526
AnaemiaBlood and lymphatic system disorders5/53017/526
HydronephrosisRenal and urinary disorders15/5308/526
Most frequent other events
Showing 10 of 54
Most frequent other events
EventDurvalumab + Gemcitabine + CisplatinGemcitabine + Cisplatin
NauseaGastrointestinal disorders281/530254/526
ConstipationGastrointestinal disorders204/530201/526
AnaemiaBlood and lymphatic system disorders200/530200/526
FatigueGeneral disorders190/530169/526
NeutropeniaBlood and lymphatic system disorders136/530163/526
Decreased appetiteMetabolism and nutrition disorders140/530131/526
Urinary tract infectionInfections and infestations124/530108/526
PyrexiaGeneral disorders107/53084/526
DiarrhoeaGastrointestinal disorders106/53074/526
VomitingGastrointestinal disorders101/53096/526

Baseline characteristics

The Full analysis set (FAS) included all randomized participants.

Age, Continuous
Age, Continuous(Years)Durvalumab + Gemcitabine + CisplatinGemcitabine + CisplatinTotal
Mean64.1 ± 8.964.6 ± 8.964.4 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab + Gemcitabine + CisplatinGemcitabine + CisplatinTotal
Female9697193
Male437433870
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + Gemcitabine + CisplatinGemcitabine + CisplatinTotal
HISPANIC OR LATINO444185
MISSING61218
NOT HISPANIC OR LATINO483477960
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab + Gemcitabine + CisplatinGemcitabine + CisplatinTotal
ASIAN152145297
BLACK OR AFRICAN AMERICAN6410
MISSING142236
OTHER718
WHITE354358712
08

Study locations

188 sites
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    New Haven, Connecticut 06520, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Geneva, Illinois 60134, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    New Orleans, Louisiana 70112, United States
  • Research Site
    Towson, Maryland 21204, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Rochester, New York 14642, United States
  • Research Site
    Bethlehem, Pennsylvania 18015, United States
  • Research Site
    Burlington, Vermont 05401, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Brisbane, 4122, Australia
  • Research Site
    Elizabeth Vale, 5112, Australia
  • Research Site
    Macquarie University, 2109, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Murdoch, 6150, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90470-340, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Rio de Janeiro, 20231-050, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    São José do Rio Preto, 15090-000, Brazil
  • Research Site
    São Paulo, 01246-000, Brazil
  • Research Site
    São Paulo, 01323-903, Brazil
  • Research Site
    São Paulo, 01509-900, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
  • Research Site
    Toronto, Ontario M5G IX6, Canada
  • Research Site
    Montreal, Quebec H2X 0C2, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Antofagasta, 1267348, Chile
  • Research Site
    Port Montt, 5480000, Chile
  • Research Site
    Santiago, 7520349, Chile
  • Research Site
    Temuco, 4810218, Chile
  • Research Site
    Temuco, 4810469, Chile
  • Research Site
    Viña del Mar, 2540488, Chile
  • Research Site
    Brno, 656 53, Czechia
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Olomouc, 77900, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Prague, 140 59, Czechia
  • Research Site
    Prague, 180 81, Czechia
  • Research Site
    Angers, 49033, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Grenoble, 38043, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Nîmes, 30029, France
  • Research Site
    Pierre-Bénite, 69495, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    Rouen, F-76031 CE, France
  • Research Site
    Bergisch Gladbach, 51465, Germany
  • Research Site
    Bonn, 53127, Germany
  • Research Site
    Cologne, 50937, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Göttingen, 37075, Germany
  • Research Site
    Herne, 44625, Germany
  • Research Site
    Jena, 07747, Germany
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Mannheim, 68167, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Nuremberg, 90491, Germany
  • Research Site
    Oldenburg, 23758, Germany
  • Research Site
    Regensburg, 93053, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Würzburg, 97080, Germany
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Kfar Saba, 95847, Israel
  • Research Site
    Petah Tikva, 4941492, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20133, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Pozzuoli, 80078, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Bunkyō City, 113-8603, Japan

Showing the first 100 of 188 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suarez C, Chang CH, Roghmann F, Ozguroglu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15. PubMed 39282910 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Apr 2024, 65 months.

Results were first posted in Jul 2025, 1 year 2 months after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 65 months is above that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2018
First posted
Nov 6, 2018
StartActual
Nov 16, 2018
Primary completionActual
Apr 29, 2024
CompletionEst.
Nov 8, 2027
Results first posted
Jul 3, 2025
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03732677
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 6, 2018
Start date
Nov 16, 2018
Primary completion
Apr 29, 2024
Completion
Nov 8, 2027 (estimated)
Results posted
Jul 3, 2025
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion